PharmaFocus Today – Page 7 – media

Johnson & Johnson’s autoimmune drug approved for new indication

On May 9, Johnson & Johnson announced that its blockbuster drug Guselkumab was approved by the National Medical Products Administration for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response, or intolerance to traditional treatments or biologics. This event marks the official entry of interleukin 23 (IL-23) targeted era into the treatment of ulcerative colitis in China. 1. China’s first As the world’s first approved fully humanized IL-23 inhibitor, guselkumab (trade name: Tenoyada) precisely regulates the immune response through a unique dual mechanism of action: it not only directly binds to the IL-23 cytokine, but also targets IL-23-enriched CD64+ inflammatory cells, blocking this core pathogenic factor that drives immune-mediated diseases such as ulcerative colitis (UC) from the source. Today, guselkumab was officially approved by the China National Medical Products Administration for the treatment of adult patients with moderate ...
- Source: drugdu
- 43
- May 14, 2025
Chairman of Baili Tianheng donates 30 million yuan to Fudan University to support the development of innovative drug target discovery and other teacher training needs

On May 12th, a reporter from The Paper learned that Zhu Yi, founder, chairman, and chief scientific officer of Sichuan Baili Tianheng Pharmaceutical Co., Ltd. (Baili Tianheng, 688506), donated RMB 30 million in cash to establish the “Fudan University Baili Tianheng Distinguished Professor” project, supporting Fudan University’s faculty construction needs in areas such as “innovative drug target discovery” and “brain and brain like intelligence research”, and strengthening the construction and development of strategic talent teams. Zhu Yi was born in 1963 and graduated with a bachelor’s degree in Radio Physics from Sichuan University. Later, he was admitted to the Master’s program in Biophysics at Fudan University and is a graduate of the Biology Department of Fudan University in 1984. Zhu Yi stated that whether it is making generic drugs or innovative drugs, there is always a knowledge framework of biology behind them. The study experience at Fudan University laid ...
- Source: drugdu
- 54
- May 13, 2025
‘This is my most important and impactful post’

On Sunday evening local time, US President Trump announced on the social platform Truth Social that he will sign an executive order at the White House tomorrow morning at 9am (21:00 Beijing time on Monday). Prescription drugs and drug prices will almost immediately decrease by 30% to 80%, and the United States will purchase drugs at the lowest prices in the world. Trump said: For many years, the world has been puzzled: why are prescription drugs and medications priced much higher in the United States than in other countries? Sometimes, the same drug, produced by the same pharmaceutical company in the same laboratory or factory, can be sold for five to ten times more in the United States than in other countries! This question is always difficult to explain and awkward, because ultimately, there is no reasonable and legitimate answer. For many years, pharmaceutical companies have consistently stated that ‘research ...
- Source: drugdu
- 52
- May 13, 2025
Adverse waist-to-height ratio trajectories during childhood linked to early cardiometabolic risk

New research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May) reveals that adverse waist-to-height ratio trajectories (a marker for central obesity) during childhood may increase cardiometabolic and cardiovascular risk at 10 years old. Notably, children with gradually increasing central obesity from birth were more likely to show early signs of metabolic and cardiovascular risk by age 10. This included elevated blood pressure and higher levels of biomarkers linked to systemic inflammation and metabolic dysfunction, such as triglycerides, insulin resistance (HOMA-IR), glycoprotein acetyls (GlycA), and high-sensitivity C-reactive protein (hs-CRP). “With rapidly rising rates of childhood obesity worldwide, it is important to understand how central obesity during childhood is already linked to early signs of metabolic deterioration, including elevated blood pressure and circulating biomarkers associated with future cardiometabolic disease.” Dr. David Horner, lead author from the University of Copenhagen, Denmark. Obesity in childhood and ...
- Source: drugdu
- 51
- May 13, 2025
Zepbound Beats Wegovy for Weight Loss in First Head-To-Head Trial of Blockbuster Drugs

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 pounds (15 kilograms). That’s according to the study funded by Lilly, which was published Sunday in the New England Journal of Medicine. Both drugs are part of a new class of medications that work by mimicking hormones in the gut and brain that regulate appetite and feelings of fullness. But tirzepatide targets two such hormones, known as GLP-1 and GIP, while semaglutide targets GLP-1 alone, said Dr. Louis Aronne, director of the Comprehensive Weight Control Center at Weill Cornell Medicine. “Two drugs together can produce better weight loss,” said Aronne, ...
- Source: drugdu
- 56
- May 13, 2025
Jiudian Pharmaceuticals received the supplementary application for change of marketing authorization holder for its drug

On May 11, Jiudian Pharmaceutical announced that the company recently received the “Notice of Approval of Supplementary Drug Application” issued by the State Drug Administration. The main content of this application is to change the drug marketing authorization holder of Dexketoprofen Tromethamine Tablets from Hunan Nona Pharmaceutical Technology Co., Ltd. to the company, and the production site remains unchanged. This drug is a non-steroidal anti-inflammatory drug and is suitable for the treatment of a variety of mild to moderate pain. According to Moentropy data, the total sales of Dexketoprofen Tromethamine Tablets in hospitals and pharmacies nationwide will be 42.01 million yuan in 2021, 55.99 million yuan in 2022, and 41.07 million yuan in 2023. The approval notice for the supplementary drug application obtained this time will further enrich the company’s product pipeline and have positive significance for optimizing the product structure. In the first quarter of 2025, Jiudian Pharmaceutical achieved ...
- Source: drugdu
- 50
- May 13, 2025
Telportide outperforms semaglutide in all weight loss goals

After announcing its own weight loss drug more than five months ago, Telpotide beats Novo Nordisk in head-to-head battle After semaglutide, multinational pharmaceutical company Eli Lilly Detailed data from the head-to-head trial were released to the public. 　　On May 12, The Paper reporter learned that Eli Lilly announced the detailed results of the SURMOUNT-5 study. The results showed that at week 72, tepoxetine achieved the primary endpoint and all five key secondary endpoints, and showed superiority over semaglutide throughout the trial. 　　Specifically, in the primary endpoint of the study, tulpoide achieved a 1.47-fold relative weight loss compared to semaglutide. Research data based on the estimated target of the treatment regimen showed that at week 72, tulpoide achieved an average weight loss of 20.2%, while semaglutide was 13.7%. The average weight loss in the tulpoide group was 22.8kg, and the average weight loss in the semaglutide group ...
- Source: drugdu
- 56
- May 13, 2025
When AAV gene therapy becomes a “discarded plan”

Recently, Johnson & Johnson’s highly anticipated bota-vec therapy failed in the Phase III clinical trial, causing it to fall heavily from the limelight stage of AAV gene therapy. 1. Phase III clinical trial failure Recently, Johnson & Johnson, which has been making great strides in the field of gene therapy, has suffered a major setback. Its highly anticipated AAV gene therapy bota-vec failed to achieve the primary endpoint of improving patients’ visual navigation ability in the Phase III LUMEOS study for the treatment of X-linked retinitis pigmentosa (XLRP). This result not only makes the future of this star therapy, which has been certified by the FDA as both a fast track and orphan drug, uncertain, but also rings the alarm bell for the field of gene therapy. As a potential first-in-class gene therapy for XLRP, bota-vec uses an adeno-associated virus vector to deliver the retinitis pigmentosa GTPase regulator (RPGR) gene, ...
- Source: drugdu
- 50
- May 13, 2025
AstraZeneca’s big move

At AstraZeneca’s first quarter 2025 earnings conference, the pharmaceutical giant dropped a bombshell on its strategic adjustment: it will officially withdraw from the field of neuroscience and instead focus resources on core areas such as weight loss and immunology. 1. Cut the pipeline AstraZeneca’s first quarter 2025 financial report showed that the company had terminated the development of a number of neuroscience projects, including MEDI1814 for the treatment of Alzheimer’s disease developed in cooperation with Eli Lilly, MEDI0618, a migraine monoclonal antibody in Phase 2 clinical trials, and MEDI7352, a dual-antibody for the treatment of diabetic neuropathy. At this point, the company’s neuroscience pipeline under development has been reduced to zero. Image source: AstraZeneca 2025 Q1 financial report The field of neuroscience is recognized as a challenging “R&D black hole” due to the extreme complexity of the brain and nervous system and the unclear pathogenesis, which leads to low clinical ...
- Source: drugdu
- 47
- May 13, 2025
Bivalirudin for injection obtains marketing authorization from the Australian Therapeutic Goods Administration

One May 6, Shuangcheng pharma announced that the company recently received the marketing authorization for bivalirudin for injection issued by the Australian Therapeutic Goods Administration. The drug is used to treat patients with medium- and high-risk acute coronary syndrome (ACS) and can be used in combination with aspirin. Previously, the company had obtained the “Drug Registration Approval” approved and issued by the National Drug Administration for the drug, and passed the National Drug Administration’s injection generic drug quality and efficacy consistency evaluation. The Australian marketing authorization will have a positive impact on the company’s expansion of overseas markets and improvement of the company’s performance. However, the export business of drugs is affected by many factors, and there is uncertainty in the sales time, market size and subsequent expansion progress. https://finance.eastmoney.com/a/202505063396845130.html
- Source: drugdu
- 69
- May 8, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.